NEWS
‘Facing the Future’: Alex Brill discusses tax code and budget challenges
In a recent episode of The Concord Coalition’s Facing the Future podcast, Alex Brill discussed with host, Bob Bixby, the evolving landscape of U.S. tax policy and what it signals for the federal budget—and investors.
2026 Portman Center Symposium: Building an Achievable Fiscal Policy
Alex Brill moderated a discussion of how US legislators can develop successful fiscal policy, featuring Carolyn Bourdeaux and Rob Portman. This conversation was a part of the Portman Center’s 2026 Symposium “Securing Our Fiscal Future: Developing Solutions to Tackle America’s Debt and Deficit.”
Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
Senator Cory Booker (D-NJ) recently proposed a bold tax plan that includes drastically increasing the standard deduction from $16,100 to $37,500 for single filers ($32,200 to $75,000 for married couples filing jointly).
FDA Continues to Expedite Biosimilar Development
Following its move in October to eliminate comparative efficacy studies for biosimilars in development, last week the FDA made further strides to streamline the biosimilar approval process in the United States.
Diminishing Returns from the Government’s Drug Negotiation Program
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
Would Senate Passage of an ACA Tax Credit Extension Matter?
Last week, under a rarely used procedure known as a discharge motion, the House of Representatives passed a three-year extension of the enhanced Affordable Care Act (ACA) healthcare tax credit, which expired on December 31.
MGA Brief Examines State and Federal PBM Mandates
Congress considered but ultimately declined to enact legislation mandating that pharmacy benefit managers (PBMs) operate in a prescribed financial arrangement with their customers.
FDA Moves to Facilitate Biosimilar Development
Yesterday, the Food and Drug Administration (FDA) announced long-overdue reforms to the biosimilar approval process that will boost biosimilar development and competition in the United States.
How Pharmaceutical Tariffs Will Affect US Health Care Costs
Tariffs on pharmaceuticals are under consideration following a Section 232 investigation into imports of medicines and active pharmaceutical ingredients (APIs).
MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
Today, MGA released a report in collaboration with the HDA measuring the economic impact of healthcare distributors in the United States.
The Unsung Hero of the OBBBA: Permanent Expensing
The One Big Beautiful Bill (OBBB), signed into law on July 4, 2025, prevented a large, scheduled tax hike from hitting American households.
Alex Brill Interviewed by Biosimilars Review & Report
Following the release of the new MGA white paper “The Long-Term Effects of Medicare Price Negotiations on Drug Competition,” Alex Brill spoke with Stanton Mehr at Biosimilars Review & Report.
MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
This week, MGA released a new white paper by Alex Brill and Christy Robinson looking at the long-term effects of Medicare price negotiations on drug competition
The 340B Program’s Negative Impact on Pharmaceutical Innovation
As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.
A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
On March 5, Speaker Ryan moderated a panel on tax policy with AEI’s Alex Brill and Kyle Pomerleau.
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
